Resmed earnings release, August 6, 2026

Resmed Inc (RMD) · Form 8-K, Item 2.02 · Filed · SEC filing

Resmed Inc. Announces Results for the Fourth Quarter of Fiscal Year 2026

Note: A webcast of Resmed’s conference call will be available at 4:30 p.m. ET today at http://investor.resmed.com

SAN DIEGO, August 6, 2026 – Resmed Inc. (NYSE: RMD, ASX: RMD) today announced results for its quarter ended June 30, 2026.

“We closed fiscal year 2026 with strong fourth quarter results, reflecting continued momentum of our global business, sustained demand for our market-leading products, and disciplined execution of our strategy,” said Resmed’s Chairman and CEO, Mick Farrell.

“Year-over-year, we delivered 9% reported revenue growth, 90 basis points of gross margin expansion, and a 16% increase in earnings per share. For full year 2026, our $1.6 billion in free cash flow enabled us to invest in innovation, strengthen our market leadership, and return more than $1 billion to our shareholders.”

“As we enter fiscal year 2027, we will leverage our global scale and enhance our digital capabilities to benefit our patients, providers, and customers.

We will use our industry-leading portfolio to improve patient outcomes, reduce healthcare costs, and drive long-term profitable growth for our shareholders.”

Financial Highlights

Other Business and Operational

Highlights

Financial Results and Operating Metrics

Unaudited; $ in millions, except for per share amounts

Discussion of Fourth Quarter Results

All comparisons are to the prior year period unless otherwise noted

Dividend program

The Resmed board of directors today declared a quarterly cash dividend of $0.66 per share, representing an increase of 10% over our previous quarterly dividend. The dividend will have a record date of August 20, 2026, payable on September 24, 2026. The dividend will be paid in U.S. currency to holders of Resmed’s common stock trading on the New York Stock Exchange. Holders of CHESS Depositary Interests (“CDIs”) trading on the Australian Securities Exchange will receive an equivalent amount in

Australian currency, based on the exchange rate on the record date, and reflecting the 10:1 ratio between CDIs and NYSE shares.

The ex-dividend date will be August 19, 2026, for common stockholders and for CDI holders. Resmed has received a waiver from the ASX’s settlement operating rules, which will allow Resmed to defer processing conversions between its common stock and CDI registers from August 19, 2026, through

August 20, 2026, inclusive.

Webcast details

Resmed will discuss its fourth quarter fiscal year 2026 results on its webcast at 1:30 p.m. U.S. Pacific Time today. The live webcast of the call can be accessed on Resmed’s Investor Relations website at investor.resmed.com. Please go to this section of the website and click on the icon for the “Q4 2026 Earnings Webcast” to register and listen to the live webcast. A replay of the earnings webcast will be accessible on the website and available approximately two hours after the live webcast. In addition, a telephone replay of the conference call will be available approximately three hours after the webcast by dialing

+1 877-660-6853 (U.S.) or

+1 201-612-7415 (outside

U.S.) and entering the passcode 13761408. The telephone replay will be available until August 20, 2026.

About Resmed

Resmed (NYSE: RMD, ASX: RMD) creates life-changing health technologies that people love. We’re relentlessly committed to pioneering innovative technology to empower millions of people in 140 countries to live happier, healthier lives. Our

AI-powered digital health solutions, cloud-connected devices and intelligent software make home healthcare more personalized, accessible and effective. Ultimately, Resmed envisions a world where every person can achieve their full potential through better sleep and breathing, with care delivered in their own home. Learn more about how we’re redefining sleep health at Resmed.com and follow @Resmed.

Safe harbor statement

Statements contained in this release that are not historical facts are “forward-looking” statements as contemplated by the Private Securities

Financial statements

Income Statement

Three Months Ended — Unaudited; $ in millions, except for per share amounts

Three Months Ended – June 30, 2026Three Months Ended – June 30, 2025Three Months Ended – % ChangeThree Months Ended – Constant Currency (A)
Revenue1,4641,3489.0%8.0%
Gross margin58.8%60.8%(200) bps
Non-GAAP gross margin (B)62.3%61.4%90 bps
Research and development expenses1068622.0%19
Selling, general, and administrative expenses29626711.0%8
Non-GAAP selling, general, and administrative expenses(B)29126510.0%7
Income from operations449455-1.0%
Operating margin30.7%33.7%(300) bps
Non-GAAP income from operations (B)5154768.0%
Non-GAAP operating margin35.2%35.3%(10) bps
Net income3833801.0%
Non-GAAP net income (B)42837514.0%
Diluted earnings per share2.642.582.0%
Non-GAAP diluted earnings per share (B)2.952.5516.0%
Operating cash flow455539-16.0%
Free cash flow(C)404508-21.0%

Income Statement

Twelve Months Ended — Unaudited; $ in millions, except for per share amounts

Twelve Months Ended – June 30, 2026Twelve Months Ended – June 30, 2025Twelve Months Ended – % ChangeTwelve Months Ended – Constant Currency (A)
Revenue5,6535,14610.0%8.0%
Gross margin61.1%59.4%170 bps
Non-GAAP gross margin (B)62.4%60.0%240 bps
Research and development expenses37833114.0%12
Selling, general, and administrative expenses1,12099313.0%10
Non-GAAP selling, general, and administrative expenses(B)1,10899112.0%9
Income from operations1,8871,68512.0%
Operating margin33.4%32.7%70 bps
Non-GAAP income from operations (B)2,0391,76316.0%
Non-GAAP operating margin36.1%34.3%180 bps
Net income1,5231,4019.0%
Non-GAAP net income (B)1,6321,40716.0%
Diluted earnings per share10.439.5110.0%
Non-GAAP diluted earnings per share (B)11.179.5517.0%
Operating cash flow1,8061,7523.0%
Free cash flow(C)1,6501,662-1.0%

Income Statement

Three Months Ended — (Unaudited; $ in thousands, except for per share amounts)

Three Months Ended – June 30, 2026Three Months Ended – June 30, 2025Twelve Months Ended – June 30, 2026Twelve Months Ended – June 30, 2025
Net revenue1,463,6471,347,9935,653,4435,146,327
Cost of sales552,245520,0682,128,0402,060,753
Amortization of acquired intangibles (1)8,3019,36731,77932,116
Masks with magnets field safety notification expenses (1)-1,512-1,512
Astral field safety notification expenses (1)41,88541,885
Total cost of sales602,431527,9232,201,7042,091,357
Gross profit861,216820,0703,451,7393,054,970
Research and development105,72686,443378,285331,284
Selling, general, and administrative290,655265,1251,108,042991,019
Acquisition and portfolio review related expenses (1)5,6282,03111,4862,031
Total selling, general, and administrative296,283267,1561,119,528993,050
Amortization of acquired intangibles (1)10,49911,92845,46645,273
Restructuring expenses (1)21,745
Total operating expenses412,508365,5271,565,0241,369,607
Income from operations448,708454,5431,886,7151,685,363
Other income (expenses), net:Interest (expense) income, net20,8855,75749,9144,114
Other income (expenses), net:Gain (loss) attributable to equity method investments2,2321,2696,9553,644
Other income (expenses), net:Gain (loss) on equity investments1,001-2,533-15,014-10,299
Other income (expenses), net:Other, net1,338-983-9,154-5,256
Other income (expenses), net:Total other income (expenses), net25,4563,51032,701-7,797
Other income (expenses), net:Income before income taxes474,164458,0531,919,4161,677,566
Other income (expenses), net:Income taxes90,73278,348396,123276,843
Other income (expenses), net:Net income383,432379,7051,523,2931,400,723
Other income (expenses), net:Basic earnings per share2.652.5910.479.55
Other income (expenses), net:Diluted earnings per share2.642.5810.439.51
Other income (expenses), net:Non-GAAP diluted earnings per share (1)2.952.5511.179.55
Other income (expenses), net:Basic shares outstanding144,706146,472145,523146,716
Other income (expenses), net:Diluted shares outstanding144,976147,037146,054147,340

Income Statement

Three Months Ended — margin” exclude amortization expense from acquired intangibles and field safety notification expenses and are reconciled below: (in thousands)

Three Months Ended – June 30, 2026Three Months Ended – June 30, 2025Twelve Months Ended – June 30, 2026Twelve Months Ended – June 30, 2025
Revenue1,463,6471,347,9935,653,4435,146,327
GAAP cost of sales602,431527,9232,201,7042,091,357
Less: Amortization of acquired intangibles (A)-8,301-9,367-31,779-32,116
Less: Masks with magnets field safety notification expenses (A)1,5121,512
Less: Astral field safety notification expenses (A)-41,885-41,885
Non-GAAP cost of sales552,245520,0682,128,0402,060,753
GAAP gross profit861,216820,0703,451,7393,054,970
GAAP gross margin58.8%60.8%61.1%59.4%
Non-GAAP gross profit911,402827,9253,525,4033,085,574
Non-GAAP gross margin62.3%61.4%62.4%60.0%

Income Statement

Three Months Ended — from operations” is reconciled with GAAP income from operations below: (in thousands)

Three Months Ended – June 30, 2026Three Months Ended – June 30, 2025Twelve Months Ended – June 30, 2026Twelve Months Ended – June 30, 2025
GAAP income from operations448,708454,5431,886,7151,685,363
Amortization of acquired intangibles—cost of sales (A)8,3019,36731,77932,116
Amortization of acquired intangibles—operating expenses (A)10,49911,92845,46645,273
Restructuring (A)21,745
Masks with magnets field safety notification expenses (A)-1,512-1,512
Astral field safety notification expenses (A)41,88541,885
Acquisition and portfolio review related expenses (A)5,6282,03111,4862,031
Non-GAAP income from operations515,021476,3572,039,0761,763,271

Income Statement

Three Months Ended — earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

Three Months Ended – June 30, 2026Three Months Ended – June 30, 2025Twelve Months Ended – June 30, 2026Twelve Months Ended – June 30, 2025
GAAP net income383,432379,7051,523,2931,400,723
Amortization of acquired intangibles—cost of sales (A)8,3019,36731,77932,116
Amortization of acquired intangibles—operating expenses (A)10,49911,92845,46645,273
Restructuring expenses (A)21,745
Gain on previously held equity investment(A)-4,353-4,353
Masks with magnets field safety notification expenses (A)-1,512-1,512
Astral field safety notification expenses (A)41,88541,885
Acquisition and portfolio review related expenses (A)5,6282,03111,4862,031
Tax benefit from business cessation(A)-21,430-21,430
Income tax effect of interest and penalties on income tax refunds (A)-29,976
Income tax effect on non-GAAP adjustments (A)-17,059-5,544-39,453-20,448
Non-GAAP net income (A)428,333374,5451,631,8481,406,777
GAAP diluted shares outstanding144,976147,037146,054147,340
GAAP diluted earnings per share2.642.5810.439.51
Non-GAAP diluted earnings per share (A)2.952.5511.179.55

Balance Sheet

June 30, 2026 — (Unaudited; $ in thousands)

June 30, 2026June 30, 2025
Current assets:Cash and cash equivalents1,469,2341,209,450
Current assets:Accounts receivable, net1,036,233939,492
Current assets:Inventories945,805927,711
Current assets:Prepayments and other current assets416,081428,952
Current assets:Assets held for sale457,386$—
Current assets:Total current assets4,324,7393,505,605
Non-current assets:Property, plant, and equipment, net581,829550,790
Non-current assets:Operating lease right-of-use assets153,167167,497
Non-current assets:Goodwill and other intangibles, net3,362,3123,511,541
Non-current assets:Deferred income taxes and other non-current assets543,903438,958
Non-current assets:Total non-current assets4,641,2114,668,786
Non-current assets:Total assets8,965,9508,174,391
Current liabilities:Accounts payable308,923278,157
Current liabilities:Accrued expenses494,921402,253
Current liabilities:Operating lease liabilities, current29,14130,506
Current liabilities:Deferred revenue162,911166,030
Current liabilities:Income taxes payable98,108132,274
Current liabilities:Short-term debt259,9509,900
Current liabilities:Liabilities held for sale41,156$—
Current liabilities:Total current liabilities1,395,1101,019,120
Non-current liabilities:Deferred revenue170,951156,803
Non-current liabilities:Deferred income taxes64,64077,682
Non-current liabilities:Operating lease liabilities, non-current137,413153,015
Non-current liabilities:Other long-term liabilities213,028141,520
Non-current liabilities:Long-term debt399,415658,392
Non-current liabilities:Total non-current liabilities985,4471,187,412
Non-current liabilities:Total liabilities2,380,5572,206,532
Stockholders’ equityCommon stock764761
Stockholders’ equityAdditional paid-in capital2,190,6142,033,599
Stockholders’ equityRetained earnings7,255,1216,081,490
Stockholders’ equityTreasury stock-2,778,591-2,073,292
Stockholders’ equityAccumulated other comprehensive income-82,515-74,699
Stockholders’ equityTotal stockholders’ equity6,585,3935,967,859
Stockholders’ equityTotal liabilities and stockholders’ equity8,965,9508,174,391

Cash Flow

Three Months Ended — (Unaudited; $ in thousands)

Three Months Ended – June 30, 2026Three Months Ended – June 30, 2025Twelve Months Ended – June 30, 2026Twelve Months Ended – June 30, 2025
Cash flows from operating activities:Net income383,432379,7051,523,2931,400,723
Adjustment to reconcile net income to cash provided by operating activities:Depreciation and amortization44,77863,628201,342198,473
Full release

Litigation Reform Act of 1995. These forward-looking statements – including statements regarding Resmed’s projections of future revenue or earnings, expenses, new product development, new product launches, new markets for its products, the integration of acquisitions, our supply chain, domestic and international regulatory developments, litigation, tax outlook, and the expected impact of macroeconomic conditions of our business – are subject to risks and uncertainties, which could cause actual results to materially differ from those projected or implied in the forward-looking statements. Additional risks and uncertainties are discussed in Resmed’s periodic reports on file with the U.S. Securities &

Exchange Commission. Resmed does not undertake to update its forward-looking statements. – More – RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Operations

(Unaudited; $ in thousands, except for per share amounts) – More – RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets

(Unaudited; $ in thousands) – More – RESMED INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows

(Unaudited; $ in thousands) – More – RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial

Measures

(Unaudited; $ in thousands, except for per share amounts)

The measures “non-GAAP gross profit” and “non-GAAP gross margin” exclude amortization expense from acquired intangibles and field safety notification expenses and are reconciled below:

The measures

“non-GAAP selling, general, and administrative expenses” and

“non-GAAP... (truncated) percentage of revenues” exclude acquisition and portfolio review related expenses and are reconciled below: – More – RESMED INC. AND SUBSIDIARIES

Reconciliation of Non-GAAP Financial

Measures

(Unaudited; $ in thousands, except for per share amounts)

The measure “non-GAAP income from operations” is reconciled with GAAP income from operations below:

The measures “non-GAAP net income” and “non-GAAP diluted earnings per share” are reconciled with GAAP net income and GAAP diluted earnings per share in the table below:

Resmed believes that non-GAAP diluted earnings per share is an additional measure of performance that investors can use to compare operating results between reporting periods. Resmed uses non-GAAP information internally in planning, forecasting, and evaluating the results of operations in the current period and in comparing it to past periods. Resmed believes this information provides investors better insight when evaluating Resmed’s performance from core operations and provides consistent financial reporting. The use of non-GAAP measures is intended to supplement, and not to replace, the presentation of net income and other GAAP measures. Like all non-GAAP measures, non-GAAP earnings are subject to inherent limitations because they do not include all the expenses that must be included under

GAAP. – More – RESMED INC. AND SUBSIDIARIES

Revenue by Product and Region

(Unaudited; $ in millions, except for per share amounts) – End –

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Resmed earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.